M/A-COM Technology Solutions
MTSI
$381.55
+5.18%
MACOM Technology Solutions Holdings, Inc. is a provider of analog, digital, and mixed-signal semiconductor solutions, serving original equipment manufacturers and distributors across industrial, medical, scientific, and test and measurement markets. The company operates as a specialized player in the semiconductor industry, focusing on a portfolio that includes integrated circuits, power transistors, amplifiers, and passive components. The current investor narrative is driven by a powerful recovery and growth story, as the company has rebounded sharply from a significant loss in early 2025 to strong profitability, with recent quarterly revenue surging 24.5% year-over-year, positioning it for potential margin expansion and market share gains in its target end markets.…
MTSI
M/A-COM Technology Solutions
$381.55
Investment Opinion: Should I buy MTSI Today?
Rating & Thesis: Hold. MTSI presents a classic 'story vs. valuation' dilemma where a powerful fundamental recovery narrative is fully, if not excessively, priced into the stock, leaving limited near-term margin of safety despite unanimous analyst bullishness.
Supporting Evidence: The stock trades at a forward P/E of 50.6x, a significant premium to most semiconductor peers, justified by its 24.5% YoY revenue growth and dramatic margin expansion to a 13.4% operating margin. Strong free cash flow generation ($132.7M TTM) and a robust balance sheet (current ratio 3.71) underpin the operational story. However, the technical picture shows the stock is overextended, trading 96.7% of the way to its 52-week high after a 167% annual gain.
Risks & Conditions: The two biggest risks are valuation multiple contraction and growth deceleration. This Hold rating would upgrade to a Buy if the stock experiences a meaningful pullback (e.g., below $230) without a deterioration in the fundamental growth story, or if forward revenue estimates are meaningfully raised. It would downgrade to a Sell if quarterly revenue growth decelerates below 15% or operating margins contract. The stock is currently overvalued relative to its own history and sector peers, pricing in perfection.
Sign up to view all
MTSI 12-Month Price Forecast
The outlook for MTSI is bifurcated between its stellar fundamental trajectory and its prohibitive valuation. The base case (55% probability) is for consolidation and volatility as the market assesses whether the company can grow into its multiples. The bull case requires flawless execution and continued market exuberance, while the bear case is a painful but plausible valuation reset. The stance is neutral due to the asymmetric risk/reward at current prices; the potential downside from multiple compression outweighs the limited near-term upside. We would become bullish on a significant pullback that improves the risk/reward profile, or bearish on any concrete sign of growth deceleration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on M/A-COM Technology Solutions's 12-month outlook, with a consensus price target around $496.02 and implied upside of +30.0% versus the current price.
Average Target
$496.02
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$305 - $496
Analyst target range
Analyst coverage for MTSI is limited, with only 3 analysts providing estimates, which is indicative of a mid-cap stock with less widespread institutional following; this can lead to higher volatility and less efficient price discovery. The average revenue estimate for the period is approximately $1.57 billion, with a tight range between high and low estimates, suggesting some consensus on the top-line outlook, but the lack of a published consensus price target or recommendation distribution prevents a clear read on sentiment. The recent institutional ratings show a pattern of sustained bullishness, with firms like Needham, Stifel, Benchmark, Truist Securities, Jefferies, and B of A Securities all maintaining 'Buy' or equivalent ratings over the past several months, and no downgrades noted in the provided data; however, without explicit price targets, the implied upside or downside cannot be quantified, and the investment thesis relies heavily on the qualitative bullish stance of these covering firms.
Bulls vs Bears: MTSI Investment Factors
The bull case for MTSI is compelling, anchored by a powerful fundamental turnaround with 24.5% revenue growth and a swing to strong profitability, all supported by robust technical momentum and unanimous analyst bullishness. However, the bear case presents a formidable counter-argument centered on an extreme valuation that prices in flawless execution, leaving the stock vulnerable to any disappointment. Currently, the bull side has stronger evidence due to the concrete, accelerating financial performance. The single most important tension in the investment debate is whether the company's explosive growth and margin expansion can be sustained long enough to grow into its sky-high valuation multiples, or if the current price already reflects an unrealistic perfection.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 24.5% year-over-year to $271.6 million, a sharp acceleration from the prior year's Q1 revenue of $218.1 million. This demonstrates successful execution of growth initiatives in industrial and medical end markets, driving the core recovery narrative.
- Dramatic Profitability Turnaround: The company swung from a net loss of $167.5 million in Q1 2025 to a net income of $48.8 million in Q1 2026, with EPS of $0.65. Gross margin expanded to 55.9% and operating margin reached 13.4%, signaling a sustainable path to profitability.
- Strong Technical Momentum: The stock is up 167.5% over the past year and trades at 96.7% of its 52-week high ($294), indicating powerful bullish momentum. Relative strength scores of 13.92 (1-month) and 25.59 (3-month) show it is significantly outperforming the broader market.
- Healthy Balance Sheet & Cash Flow: A strong current ratio of 3.71 and manageable debt-to-equity of 0.41 provide financial flexibility. The company generated $42.9M in operating cash flow last quarter and has TTM free cash flow of $132.7M, funding growth internally.
Bearish
- Extremely High Valuation Premium: With a forward P/E of 50.6x, P/S of 9.75x, and an astronomical EV/EBITDA of 247.6x, MTSI trades at a massive premium to typical sector multiples. This leaves no room for execution error and implies near-perfect growth expectations are already priced in.
- Proximity to Technical Resistance: Trading at $284.18, the stock is just 3.3% below its 52-week high of $294.00. After a 167% run, failure to break this resistance could trigger a significant pullback, as evidenced by the stock's 19.7% maximum drawdown and high beta of 1.48.
- Limited Analyst Coverage & Price Discovery: Only 3 analysts provide estimates, indicating a mid-cap stock with less institutional following. The lack of a published consensus price target or target range creates higher volatility and less efficient price discovery, increasing investor risk.
- Growth Deceleration Risk: The 24.5% YoY revenue growth, while strong, must be sustained to justify the premium valuation. Any sign of deceleration in upcoming quarters, especially from the industrial and medical end markets, would likely trigger a severe multiple contraction.
MTSI Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 167.54% gain over the past year. As of the latest close at $284.18, the price is trading near the top of its 52-week range, approximately 96.7% of the way from its low of $108.21 to its high of $294.00, indicating strong momentum but also proximity to a key technical resistance level which could signal potential overextension. Recent short-term momentum remains exceptionally strong, with the stock up 23.90% over the past month and 29.73% over the past three months, significantly outpacing the broader market as shown by its 13.92 and 25.59 relative strength scores, respectively; this acceleration suggests the bullish trend is intact, though the 1-month gain is slightly less than the 1-year pace, which may hint at a potential consolidation phase after such a massive run. Key technical support is anchored at the 52-week low of $108.21, while immediate resistance sits at the 52-week high of $294.00; a decisive breakout above $294 would signal a continuation of the bull trend, whereas a failure could lead to a pullback towards recent consolidation zones around $260. The stock's beta of 1.481 indicates it is approximately 48% more volatile than the S&P 500, which is critical for risk management as it implies larger price swings in both directions, consistent with the observed 19.74% maximum drawdown.
Beta
1.60
1.60x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$118-$385
Price range past year
Annual Return
+209.6%
Cumulative gain past year
| Period | MTSI Return | S&P 500 |
|---|---|---|
| 1m | +44.7% | +8.2% |
| 3m | +59.7% | +9.0% |
| 6m | +134.8% | +10.5% |
| 1y | +209.6% | +26.5% |
| ytd | +118.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MTSI Fundamental Analysis
Revenue growth has accelerated significantly, with the most recent Q1 2026 revenue reaching $271.61 million, representing a robust 24.52% year-over-year increase; this marks a sharp reversal from the trend a year prior, where Q1 2025 revenue was $218.12 million, and indicates the company is successfully executing on its growth initiatives across its industrial and medical end markets. Profitability has dramatically improved, with the company reporting net income of $48.77 million and a gross margin of 55.88% for Q1 2026, a stark contrast to the net loss of $167.53 million in Q1 2025; operating margin has expanded to 13.40%, and the quarterly EPS of $0.65 demonstrates a clear path to sustained profitability after a period of significant losses. The balance sheet and cash flow position are healthy, with a strong current ratio of 3.71, a manageable debt-to-equity ratio of 0.405, and trailing twelve-month free cash flow of $132.74 million; the company generated $42.93 million in operating cash flow last quarter, providing ample internal funding for growth, and its return on assets of 4.92% indicates efficient use of its asset base.
Quarterly Revenue
$271612000.0B
2026-01
Revenue YoY Growth
+0.24%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$132736999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MTSI Overvalued?
Given the company's positive net income in the most recent quarter, the primary valuation metric selected is the forward P/E ratio. The forward P/E stands at 50.61x, which is the relevant figure as the trailing P/E is negative (-173.89x) due to prior period losses; the forward multiple reflects the market's expectation of sustained future earnings growth following the company's return to profitability. Compared to sector averages, MTSI's valuation appears elevated, trading at a significant premium based on its price-to-sales ratio of 9.75x and EV/EBITDA of 247.63x; this premium is likely being assigned due to the company's high growth trajectory (24.5% YoY revenue growth) and margin expansion story, though the extreme EV/EBITDA multiple suggests expectations are very high. Historically, the stock's current forward P/E of ~50x is above its own historical range observed in recent quarters, where it has fluctuated widely; for instance, its PE ratio was 52.23x at the end of Q4 2025. Trading near the upper end of its own historical valuation band suggests the market is pricing in an optimistic outlook for continued execution, leaving little room for disappointment.
PE
-173.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -15x~133x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
247.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, not operational weakness. The company's forward P/E of 50.6x and EV/EBITDA of 247.6x are extraordinarily high, meaning the stock is priced for sustained hyper-growth. If quarterly revenue growth decelerates from the current 24.5% rate or margins fail to expand further, a severe derating is likely. While the balance sheet is healthy (D/E 0.41), the small earnings base (Q1 net income of $48.8M) provides little cushion against a multiple contraction.
Market & Competitive Risks: As a stock with a beta of 1.48, MTSI is 48% more volatile than the market and highly sensitive to sector-wide rotations out of growth and semiconductor stocks. Trading at a massive premium to sector averages on P/S (9.75x) and EV/EBITDA, it is acutely vulnerable to a broader compression in growth stock valuations, potentially triggered by higher interest rates. Competitive risks are inherent in the analog semiconductor space, where pricing pressure and rapid technological change could threaten the margin expansion story that is critical to the thesis.
Worst-Case Scenario: The worst-case scenario involves a 'growth scare' where MTSI misses revenue estimates or guides growth lower, combined with a broader market sell-off in high-multiple stocks. This could trigger a cascade of analyst downgrades and rapid multiple compression. A realistic downside could see the stock re-test its 52-week low of $108.21, representing a potential loss of approximately -62% from the current price of $284.18. More conservatively, a pullback to the $200 level (-30%) is plausible if the technical uptrend breaks and growth moderates.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: The extreme multiples (50.6x forward P/E) make the stock hypersensitive to any growth disappointment, with high downside potential. 2) Execution Risk: The company must sustain its 24.5% revenue growth and margin expansion to justify its price; deceleration would be punished. 3) Market Risk: With a beta of 1.48, the stock is highly volatile and would likely fall more than the market in a downturn. 4) Liquidity & Coverage Risk: Limited analyst coverage (only 3 firms) can lead to sharper price moves on news and less efficient price discovery.
Our 12-month forecast outlines three scenarios. The Base Case (55% probability) sees the stock consolidating between $260 and $300 as growth moderates and the valuation digests its prior gains. The Bull Case (25% probability) projects a breakout to $320-$350 if growth accelerates and margins expand further. The Bear Case (20% probability) warns of a drop to $180-$220 if growth decelerates sharply, triggering multiple compression. The Base Case is most likely, assuming the company meets but does not exceed current high expectations. The key assumption is that revenue growth remains in the high-teens for the full year.
MTSI is significantly overvalued based on traditional valuation metrics. Its forward P/E of 50.6x and price-to-sales ratio of 9.75x represent a large premium to the broader semiconductor sector. The extreme EV/EBITDA multiple of 247.6x is a clear signal that expectations are extraordinarily high. The valuation implies the market expects the company to sustain its 24.5% revenue growth rate and continue expanding margins for several years. Any deviation from this optimistic path will likely result in a sharp derating.
MTSI is a high-risk, high-reward proposition at its current price. For investors who already own it, the strong fundamentals support holding. For new buyers, the stock is less attractive because its valuation (50.6x forward P/E) prices in near-perfect execution, leaving little margin for error. It could be a good buy for very aggressive growth investors on a significant pullback (e.g., below $230), which would improve the risk/reward profile. The unanimous 'Buy' ratings from analysts are counterbalanced by the extreme multiples and technical overextension.
MTSI is more suitable for a medium-to-long-term investment horizon of 2-3 years for investors who believe in the sustainability of its turnaround. Its high beta (1.48) and valuation sensitivity make it a poor candidate for short-term trading, as news-driven volatility can be severe. Long-term holders are betting the company can grow into its valuation over time. There is no dividend, so total return relies entirely on price appreciation. Given the current elevated price, a patient approach is required, with a minimum suggested holding period of 18-24 months to allow the fundamental story to unfold.